DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results
02 Mai 2022 - 10:00PM
Montrouge, France, May 2, 2022
DBV Technologies Reports Recent Business Developments
and First Quarter 2022 Financial Results
- The U.S. Food and Drug Administration (FDA) has granted DBV
Technologies a Type C meeting to align on the new Viaskin Peanut
Phase 3 study protocol
- The study protocol was recently submitted to the FDA as part of
the Type C briefing materials
DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 –
Nasdaq Stock Market: DBVT), a clinical-stage specialty
biopharmaceutical company, today announced business updates
concerning the regulatory status for its lead product candidate,
Viaskin Peanut. The Company also reported financial results for the
first quarter of 2022. The quarterly financial statements were
approved by the Board of Directors on April 29, 2022.
To download the full version of the Press Release in English
language, please click on the following link: PDF Version
DBV Technologies (EU:DBV)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
DBV Technologies (EU:DBV)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024